Surgical Decision-Making for Incidental Adnexal Masses

Abstract

Incidental adnexal masses are frequently encountered in clinical practice, particularly with the widespread use of advanced imaging modalities. The optimal surgical approach to these findings requires careful consideration of epidemiology, underlying pathophysiology, risk stratification, clinical presentation, and evolving evidence-based guidelines. This review synthesizes recent literature and expert recommendations to provide a comprehensive, mechanism-based framework for the surgical management of incidental adnexal masses. Special focus is given to individualized patient assessment, intraoperative decision-making, risk-benefit analysis, and future directions in minimally invasive and fertility-sparing techniques.

Introduction

Incidental adnexal masses are increasingly identified due to the proliferation of imaging for unrelated abdominal and pelvic complaints. These findings present a clinical conundrum: while most are benign, a minority represent malignancy or clinically significant pathology. Surgical decision-making thus hinges on accurate differentiation, balancing the risks of unnecessary intervention against the potential for missed or delayed diagnosis of ovarian or tubal cancer. This article critically reviews current evidence, diagnostic modalities, and guideline-driven approaches to inform optimal management strategies for healthcare professionals.

Epidemiology / Disease Burden

Adnexal masses are detected in up to 10% of women undergoing pelvic imaging, with prevalence increasing with age and use of high-resolution ultrasonography and cross-sectional imaging. In premenopausal women, the vast majority are benign functional cysts, whereas postmenopausal women exhibit a higher proportion of neoplastic and malignant lesions. The lifetime risk of ovarian cancer is approximately 1.3%, but many more women undergo surgical intervention for suspected malignancy. The burden of unnecessary surgery, associated morbidity, and healthcare costs underscores the necessity for precise risk stratification and judicious surgical planning.

Pathophysiology

Adnexal masses encompass a heterogeneous group of lesions, including functional ovarian cysts, benign neoplasms (serous/mucinous cystadenomas, mature teratomas), endometriomas, tubo-ovarian abscesses, and malignant tumors. Pathogenesis varies: functional cysts arise from normal ovulatory processes, whereas neoplastic lesions reflect dysregulated cellular proliferation. Malignant transformation is associated with genetic mutations (BRCA1/2, p53), hormonal influences, and chronic inflammation. Pathophysiological understanding informs risk stratification, as features such as solid components, papillary projections, and rapid growth are predictive of malignancy and influence surgical urgency and extent.

Risk Factors

Key risk factors for malignancy in adnexal masses include advanced age, postmenopausal status, family history of ovarian or breast cancer, nulliparity, endometriosis, genetic predisposition (BRCA mutations, Lynch syndrome), and prior history of gynecologic malignancies. Hormonal factors, such as prolonged estrogen exposure, also play a role. Clinical risk assessment tools integrate these variables to guide management, with the Risk of Malignancy Index (RMI), International Ovarian Tumor Analysis (IOTA) models, and American College of Obstetricians and Gynecologists (ACOG) guidelines serving as cornerstones of contemporary practice.

Clinical Features

Most incidental adnexal masses are asymptomatic, discovered during imaging for unrelated complaints. When present, symptoms are typically nonspecific: abdominal fullness, pelvic pain, bloating, or menstrual irregularities. Acute presentations (torsion, rupture, hemorrhage) demand urgent intervention but are infrequent. Physical examination is often unremarkable, especially for small or mobile lesions. Clinical suspicion for malignancy increases with constitutional symptoms (weight loss, early satiety, ascites) or palpable fixed, solid masses. Thorough history and examination, though not diagnostic alone, are essential for contextualizing imaging findings and guiding further workup.

Diagnosis

Transvaginal ultrasonography (TVUS) is the first-line imaging modality for characterizing adnexal masses, offering high sensitivity for lesion morphology, size, septations, papillary projections, and vascularity (Doppler assessment). The IOTA Simple Rules and ADNEX model aid in stratifying risk based on sonographic features. In select cases, MRI or CT may clarify indeterminate findings or assess extra-ovarian spread. Serum biomarkers, notably CA-125, HE4, and risk algorithms (ROMA), are adjunctive, with the caveat that CA-125 is nonspecific and elevated in many benign conditions. Definitive diagnosis often requires histopathological evaluation, emphasizing the importance of careful intraoperative assessment and, when indicated, frozen section analysis.

Treatment & Management

The management of incidental adnexal masses is individualized based on patient age, menopausal status, sonographic features, tumor markers, and comorbidities. Expectant management is appropriate for simple, unilocular cysts less than 5 cm in premenopausal and less than 3 cm in postmenopausal women, provided they are asymptomatic and lack concerning features. Surgical intervention is warranted for masses with solid components, papillary projections, rapid growth, elevated tumor markers, or symptomatic presentation. Minimally invasive approaches (laparoscopy) are preferred when feasible, with intraoperative measures to minimize cyst rupture and spillage. Fertility preservation is a priority in reproductive-age women, with cystectomy favored over oophorectomy when oncologically safe. Intraoperative frozen section and consultation with gynecologic oncology are recommended for suspicious or indeterminate lesions.

Recent Advances / Emerging Therapies

Recent advances include refined ultrasonographic scoring systems (IOTA, O-RADS), which improve preoperative risk stratification and reduce unnecessary surgery. Developments in laparoscopic and robotic-assisted techniques have enhanced the safety and scope of minimally invasive management, even for larger or complex masses. Molecular profiling and liquid biopsy approaches hold promise for future non-invasive malignancy prediction. The integration of artificial intelligence into imaging analysis is emerging, offering potential for automated, accurate triage of adnexal masses. Ongoing trials are evaluating novel biomarkers, targeted therapies, and fertility-sparing protocols for borderline and early-stage malignant lesions.

Guideline Recommendations

Leading societies (ACOG, ESGO, RCOG) emphasize individualized, risk-adapted management. Asymptomatic, simple cysts in low-risk women are managed expectantly with interval imaging. Surgical removal is indicated for complex or symptomatic masses, or when malignancy cannot be excluded. Laparoscopy is preferred for presumed benign lesions, while open surgery and gynecologic oncologist involvement are advocated for high-risk or suspicious masses. Routine use of CA-125 and IOTA/O-RADS models is recommended for preoperative triage. Shared decision-making, informed consent, and consideration of reproductive goals are integral to patient-centered care.

Conclusion

Surgical decision-making for incidental adnexal masses requires a nuanced, evidence-based approach that incorporates epidemiological trends, risk assessment, and the latest advances in diagnostic and surgical techniques. Individualized management, guided by imaging, biomarkers, and patient preferences, optimizes clinical outcomes while minimizing unnecessary interventions. Ongoing research and the integration of emerging technologies promise further refinements in the safe, effective care of women with incidental adnexal masses.